CUHK study finds mainland cancer drug to be effective
CUHK study finds mainland cancer drug to be effective
CUHK researchers say the drug D3S-001 has shown promise during a phase 1 trial. Photo: RTHK
Chinese University medical researchers on Monday said a multinational study they led has found a mainland-developed cancer drug to be effective in treating tumours.
They said the drug D3S-001, from company D3Bio, has shown promise during a phase 1 trial involving patients with cancers of the lung, pancreas and colon that are driven by KRAS-G12C gene mutations.
More than 70 percent of those who took part in the trial saw their tumours shrink significantly or disappear altogether, the researchers said.
Associate professor at the university's department of clinical oncology, Dr Herbert Loong, said the new drug is more effective than previous treatments.
"In the sense that it does inhibit KRAS-G12C at a quicker rate and most likely at a longer duration as well," Loong said.
Professor Tony Mok, who chairs the department, said further study is needed.
"We are actually looking into a phase three development, most likely we would like to see this compound as a first-line medication," Mok said.
The researchers said their findings have been published in the Nature Medicine journal.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
20-05-2025
- South China Morning Post
Hong Kong's CUHK eyes scholars from US amid higher education turmoil in country
The president of the Chinese University of Hong Kong (CUHK) has said his institution will study how to use research funding to attract top academics who left US institutions amid the Trump administration's battle with higher education in the country. Professor Dennis Lo Yuk-ming also said the recent tariff tensions between China and the US had driven up the prices of equipment and chemicals from the country, and his university found it difficult to procure them for research purposes. Lo, who was installed as the ninth vice-chancellor and president of CUHK in a ceremony on Tuesday, said in his address that Hong Kong was now in an ever-changing era and was constantly facing complex and unexpected clashes. 'As a knowledge hub and cradle of talent, the university has to target, show resilience and be flexible in dealing with storms more than ever before,' he said. Lo said with some academics in the US leaving the country following President Donald Trump's recent clash with elite private universities, his team would study how to offer more research subsidies to attract these foreign scholars. 'I hope CUHK will become their first choice … geopolitics brings crises and opportunities and allows us to have opportunities to hire academics elsewhere,' he said. But he said the university found it harder and more expensive to purchase some equipment and reagents for its Shenzhen Research Institute.
RTHK
19-05-2025
- RTHK
CUHK study finds mainland cancer drug to be effective
CUHK study finds mainland cancer drug to be effective CUHK researchers say the drug D3S-001 has shown promise during a phase 1 trial. Photo: RTHK Chinese University medical researchers on Monday said a multinational study they led has found a mainland-developed cancer drug to be effective in treating tumours. They said the drug D3S-001, from company D3Bio, has shown promise during a phase 1 trial involving patients with cancers of the lung, pancreas and colon that are driven by KRAS-G12C gene mutations. More than 70 percent of those who took part in the trial saw their tumours shrink significantly or disappear altogether, the researchers said. Associate professor at the university's department of clinical oncology, Dr Herbert Loong, said the new drug is more effective than previous treatments. "In the sense that it does inhibit KRAS-G12C at a quicker rate and most likely at a longer duration as well," Loong said. Professor Tony Mok, who chairs the department, said further study is needed. "We are actually looking into a phase three development, most likely we would like to see this compound as a first-line medication," Mok said. The researchers said their findings have been published in the Nature Medicine journal.
South China Morning Post
19-05-2025
- South China Morning Post
Mainland Chinese drug effective in treating 3 cancer types: Hong Kong-led study
A new drug developed by a mainland Chinese biotechnology company is effective in combating three types of cancer that currently have limited treatment options, a multinational study led by the Chinese University of Hong Kong (CUHK) has found. University researchers said on Monday that the novel drug, D3S-001, can treat non-small-cell lung, colorectal, and pancreatic cancers triggered by the gene mutation KRAS-G12C. The drug is said to be a 'next-generation' inhibitor for the gene mutation, which can currently only be treated using a limited number of therapeutic options. 'It does inhibit KRAS-G12C at a quicker rate and most likely at a longer duration as well [compared with a first-generation inhibitor],' said Dr Herbert Loong Ho-fung, an associate professor at CU Medicine's clinical oncology department. 'This is demonstrated in the laboratory and certainly in our clinical trials. We're also seeing signals of this in our patients.' Loong said phase one of the drug's clinical trial found that 70 per cent of the 42 participating patients who received the inhibitor for the first time saw a significant shrinkage or disappearance of their tumours.
